Article: GlaxoSmithKline's Rotavirus Vaccine Candidate Shown Effective Against Rotavirus Disease.

Data Published in New England Journal of Medicine Establishes Safety Profile of New Rotavirus Vaccine Candidate

PHILADELPHIA, Jan. 4 /PRNewswire-FirstCall/ -- Data from one of the largest infant vaccine trials ever conducted, published today in the New England Journal of Medicine (NEJM), showed GlaxoSmithKline's (GSK) rotavirus vaccine candidate as effective against rotavirus disease (rotavirus gastroenteritis) in the first year of life. Rotavirus is the leading recognized cause of diarrhea-related illness and death among infants and young children. Every year, rotavirus is associated with an estimated 25 million clinic visits, two million hospitalizations and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!